Some of these therapies have been translated for use in type 1 diabetes patients: treatment with CTLA-4-Ig was successful in delaying disease, but was not successful in reversing disease course, with continued loss of C-peptide, a byproduct of insulin processing that is a marker of endogenous insulin production (137, 138). This evidence concerns the gene INS and type 1 diabetes mellitus.